Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

NCT03271047 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03271047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03271047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 18, 2017
Completion date
February 25, 2021
Enrollment
75 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

mss, ras-mutant colorectal cancer